Brief: Shield Therapeutics Reiterates Guidance To Meet $31.5 Mln Revenue Target For 2024
21/11/2024 07:54
Nov 21 (Reuters) - Shield Therapeutics PLC STXS.L :
* SHIELD THERAPEUTICS - BUSINESS UPDATE
* SHIELD THERAPEUTICS PLC - RECRUITMENT COMPLETED FOR PHASE
3
STUDY IN CHINA FOR IBD AND IDA
* SHIELD THERAPEUTICS PLC - GUIDANCE REITERATED TO MEET
$31.5
MILLION REVENUE TARGET FOR 2024
Source text: ID:nRSU0479Na
Further company coverage: STXS.L
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update